首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1918186

基因檢測市場－2026-2031年預測

Hereditary Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月16日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

基因檢測市場預計將從 2025 年的 36.72 億美元成長到 2031 年的 60.58 億美元，複合年成長率為 8.7%。

基因檢測市場涵蓋了複雜且快速發展的分子診斷領域，專注於識別與遺傳疾病、疾病易感性和藥物反應相關的基因變異。該市場是精準醫療模式的核心，它將患者照護從被動治療轉變為主動風險評估和個人化管理策略。

核心臨床價值與應用範圍

基因檢測透過分析個體的DNA提供重要的資訊。具體應用包括：檢測可能導致遺傳性疾病的突變（診斷性檢測）、預測癌症等遺傳性疾病的風險（預測性/易感性檢測）以及輔助藥物選擇和劑量決策（藥物遺傳學）。其應用領域涵蓋產前和新生兒篩檢、腫瘤學、心臟病學、神經病學和藥物治療。基因檢測的根本價值在於能夠實現早期療育、指南後續觀察、為治療方案選擇提供依據，並促進家族內部的級聯檢測，從而改善臨床療效並最佳化醫療資源配置。

主要市場成長促進因素

市場擴張是由幾個強勁的協同趨勢所驅動的。全球癌症發生率的上升是主要促進因素，尤其是那些具有明確遺傳傾向的癌症，例如乳癌、卵巢、大腸直腸癌和胰腺癌。在公共衛生宣傳活動和專業指南的推動下，臨床醫生和患者對遺傳性癌症症候群的認知不斷提高，這刺激了對生殖系檢測的需求，以指南風險管理、手術決策和生育計劃。

同時，藥物基因體學（PGx）與主流臨床實踐的融合顯著拓展了其應用領域。 PGx檢測擴大被用於指南多種治療藥物的處方，包括抗憂鬱症、抗血小板藥和化療藥物，並根據個體的基因組成預測療效和不利事件風險。專家共識指南的發布和標準化檢測方案的開發提高了臨床可靠性，並加速了其在醫療保健系統中的應用。

技術進步，特別是次世代定序（NGS）技術的廣泛應用和成本下降，是市場成長的根本驅動力。 NGS能夠同時分析多個基因，甚至整個EXOME/基因組，取代了傳統的單基因順序檢測。這項技術飛躍顯著提高了基因檢測的通量、範圍和發現能力，使全面的檢測組合和廣泛的基因組分析更容易獲取，也更具臨床可行性。

政府和機構的支持也是關鍵促進因素。國家公共衛生項目，新生兒篩檢篩檢，能夠提高基因篩檢的可近性，直接增加檢測量。此外，衛生部門和醫學協會制定法規結構和專業指南，有助於檢測方法的標準化、品質保證和完善報銷機制，進而使基因檢測合法化並納入標準治療通訊協定。

The hereditary testing market encompasses a sophisticated and rapidly evolving segment of molecular diagnostics focused on identifying genetic variants associated with inherited disorders, disease predisposition, and drug response. This market is central to the paradigm of precision medicine, transforming patient care from reactive treatment to proactive risk assessment and personalized management strategies.

Core Clinical Value and Application Spectrum

Hereditary testing provides critical insights by analyzing an individual's DNA to detect mutations that may be causative for genetic disorders (diagnostic testing), indicate an elevated risk for developing conditions such as hereditary cancers (predictive/predispositional testing), or inform medication selection and dosing (pharmacogenomics). Its applications span prenatal and newborn screening, oncology, cardiology, neurology, and pharmacotherapy. The fundamental value lies in enabling earlier intervention, guiding targeted surveillance, informing therapeutic choices, and facilitating cascade testing within families, thereby improving clinical outcomes and optimizing healthcare resource allocation.

Primary Market Growth Drivers

Market expansion is propelled by several powerful and synergistic trends. The rising global prevalence of cancer, particularly those with known hereditary components such as breast, ovarian, colorectal, and pancreatic cancers, is a paramount driver. Increased awareness of hereditary cancer syndromes among both clinicians and patients, fueled by public health campaigns and professional guidelines, is stimulating demand for germline testing to inform risk management, surgical decisions, and family planning.

Concurrently, the integration of pharmacogenomics (PGx) into mainstream clinical practice is creating a substantial new application segment. PGx testing is increasingly utilized to guide prescribing for a range of therapeutics, including antidepressants, antiplatelets, and chemotherapeutic agents, by predicting efficacy and adverse event risk based on an individual's genetic makeup. The publication of professional consensus guidelines and the development of standardized testing panels are lending clinical credibility and accelerating adoption across healthcare systems.

Technological advancement, particularly the widespread adoption and decreasing cost of next-generation sequencing (NGS), is the foundational enabler of market growth. NGS allows for the simultaneous analysis of multiple genes or even the entire exome/genome, replacing older, sequential single-gene tests. This technological leap has vastly increased the throughput, scope, and discovery power of hereditary testing, making comprehensive panels and broader genomic analyses more accessible and clinically feasible.

Supportive governmental and institutional initiatives are also critical catalysts. National public health programs that expand access to genetic screening-such as universal non-invasive prenatal testing (NIPT) or newborn screening expansions-directly drive test volumes. Furthermore, the development of regulatory frameworks and professional guidelines by health authorities and medical societies helps standardize testing practices, ensure quality, and bolster reimbursement pathways, thereby legitimizing and integrating genetic testing into standard care protocols.

Key Application and Technology Segments

The market is segmented by both application and technology. The oncology segment remains the largest and most dynamic, driven by the clinical utility of testing for hereditary breast and ovarian cancer (HBOC) and Lynch syndrome, among others. The pharmacogenomics segment is experiencing rapid growth as evidence accumulates and implementation barriers are addressed.

From a technological standpoint, NGS-based multi-gene panels dominate the landscape for hereditary cancer and comprehensive disorder testing. However, targeted testing methods for specific high-penetrance variants and array-based technologies for pharmacogenomics also maintain significant roles. The continuous evolution of bioinformatics pipelines for variant interpretation is a critical, albeit less visible, component of the technological ecosystem.

Geographic Landscape and Regulatory Environment

Europe represents a leading and mature market, characterized by well-established healthcare infrastructures, a high degree of technological adoption, and proactive regulatory and professional bodies that issue testing guidelines. The presence of major diagnostic companies and a supportive environment for genetic services contribute to the region's significant market share.

Globally, the market is shaped by distinct regional regulatory frameworks governing test approval, laboratory licensing, and data privacy. These variations influence the pace of new test introductions and commercial strategies. Markets with clearer reimbursement mechanisms for genetic tests typically exhibit faster adoption and more robust competition among providers.

Competitive Landscape and Strategic Evolution

The competitive landscape is diverse, including large commercial diagnostic laboratories, specialized genetic testing companies, and in-house hospital laboratories. Strategic activities are intensely focused on research and development to expand test menus, improve variant classification, and reduce turnaround times. Key players are engaged in securing regulatory clearances for their tests, publishing clinical validity and utility data in peer-reviewed journals, and forming strategic partnerships with academic medical centers, pharmaceutical companies, and health systems to integrate testing into clinical pathways.

Future Market Trajectory

The future trajectory of the hereditary testing market points toward greater integration, automation, and data-driven insights. Testing will move further into routine primary and specialty care as clinical decision support tools become more embedded in electronic health records. The application of artificial intelligence and machine learning to improve variant interpretation and risk prediction will enhance the value of genomic data.

Market growth will be sustained by the ongoing discovery of new gene-disease associations, the expansion of polygenic risk scores for common diseases, and the continuous decrease in sequencing costs. However, success will also depend on effectively addressing challenges related to equitable access, genetic counseling workforce capacity, data privacy, and the responsible communication of complex results. As a cornerstone of modern, preventative, and personalized medicine, the hereditary testing market is poised for sustained expansion, driven by irreversible advances in genomic science and a deepening understanding of the genetic basis of health and disease.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2025 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Hereditary Testing Market Segmentation

By Disease Type
Hereditary Cancer Testing
Hereditary Non-Cancer Testing
By Technology
Cytogenetic
Biochemical
Molecular Testing
By End-User
Hospitals
Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEREDITARY TESTING MARKET BY DISEASE TYPE

5.1. Introduction
5.2. Hereditary Cancer Testing
5.3. Hereditary Non-Cancer Testing

6. HEREDITARY TESTING MARKET BY TECHNOLOGY

6.1. Introduction
6.2. Cytogenetic
6.3. Biochemical
6.4. Molecular Testing

7. HEREDITARY TESTING MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others

8. HEREDITARY TESTING MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others